Solid Biosciences Inc. filings document regulatory disclosures for a Nasdaq-listed precision genetic medicine company developing gene therapies for rare neuromuscular and cardiac diseases. Its SEC records include Form 8-K reports on operating and financial results, Regulation FD presentations, clinical updates for SGT-003 and the INSPIRE DUCHENNE trial, material agreements, and capital-structure matters.
Proxy filings describe annual stockholder meeting proposals, board classification matters, advisory votes, executive compensation, and equity awards. The filing record also identifies the company’s common stock as listed on The Nasdaq Global Select Market under the SLDB symbol.
Solid Biosciences reported a larger quarterly loss as it ramped investment in its gene therapy pipeline. For the three months ended March 31, 2026, net loss was $56.7 million compared with $39.3 million a year earlier, driven mainly by higher research and development spending.
Research and development expenses rose to $46.1 million from $30.9 million, reflecting manufacturing and clinical costs for lead Duchenne candidate SGT‑003 and increased activity in SGT‑212 for Friedreich’s ataxia. General and administrative expenses increased to $11.2 million from $9.1 million.
The company strengthened its balance sheet through a March 2026 private placement and at‑the‑market sales, lifting total assets to $422.9 million and stockholders’ equity to $374.1 million as of March 31, 2026. Cash, cash equivalents and available‑for‑sale securities were $380.7 million, which management expects will fund operations into the first half of 2028.
Solid Biosciences Inc. ownership filing: Reporting persons led by Invus Public Equities and affiliated entities report collective beneficial ownership of 10,066,682 shares, equal to 9.99% of issued and outstanding common stock as of March 31, 2026.
The total consists of 7,690,405 Shares and 2,376,277 Warrants exercisable one-for-one; calculations use 98,391,314 Shares outstanding as of March 16, 2026. The Warrants contain a Beneficial Ownership Limitation that prevents exercise that would raise ownership above 9.99% (changeable by a holder upon 61 days' notice).
BlackRock, Inc. reports beneficial ownership of 4,578,650 shares (4.7%) of Solid Biosciences Inc. common stock as of 03/31/2026. The filing (Schedule 13G/A, CUSIP 83422E204) shows sole voting power of 4,515,473 and sole dispositive power of 4,578,650. The amendment was signed on 04/27/2026 by Spencer Fleming, Managing Director.
Solid Biosciences Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 10, 2026. The company seeks to elect three Class II directors to terms ending in 2029 and ratify the advisory appointment of co‑founder Ilan Ganot as a Class I director through 2028.
Stockholders are also asked to ratify PricewaterhouseCoopers LLP as auditor for 2026, approve an amendment doubling authorized common stock from 240,000,000 to 480,000,000, and cast an advisory “say‑on‑pay” vote on executive compensation. The record date is April 16, 2026, with 98,413,277 common shares entitled to one vote each.
Howton David T reported acquisition or exercise transactions in this Form 4 filing.
Solid Biosciences Inc. reported that Chief Operating Officer David T. Howton received a grant of 79,341 restricted stock units (RSUs), each representing a contingent right to one share of common stock. These RSUs relate to performance stock units granted on June 11, 2024, where 25% of the target RSUs vest upon each of four predetermined performance milestones.
The Board determined that the second performance milestone was met on January 29, 2026, triggering this portion of the award. The shares tied to this milestone are scheduled to vest in the first quarter of 2027, subject to Mr. Howton’s continued service with the company on the evaluation date. This is a compensation-related equity award, not an open-market stock purchase.
Brooks Gabriel reported acquisition or exercise transactions in this Form 4 filing.
Solid Biosciences Inc. Chief Medical Officer Brooks Gabriel reported an award of 58,847 restricted stock units (RSUs) tied to performance stock units. Each RSU represents a right to receive one share of common stock as it vests. These RSUs relate to the second of four performance milestones under PSUs originally granted on June 11, 2024.
The Board determined that the performance criteria for the second milestone were met on January 29, 2026. The associated RSUs will vest only if Gabriel continues to serve the company through the Evaluation Date, which is anticipated to occur in the first quarter of 2027.
Solid Biosciences Inc. reported that President and CEO Alexander Cumbo acquired 169,401 restricted stock units (RSUs), each representing one share of common stock. These RSUs relate to performance stock units granted on June 11, 2024, which vest in four 25% performance tranches.
The Board determined that the performance criteria for the second Performance Milestone were met on January 29, 2026. Shares tied to this milestone will vest only if Cumbo continues serving with the company through the Evaluation Date, which is anticipated in the first quarter of 2027.
Solid Biosciences Inc. reported that Chief Technology Officer Paul Herzich acquired 54,925 restricted stock units (RSUs) linked to the company’s common stock as part of his equity compensation. These RSUs were earned under performance stock units (PSUs) originally granted on June 11, 2024.
The PSUs vest in four equal 25% tranches upon achieving independent, pre-set performance milestones tied to business objectives. The Board determined the second milestone was met on January 29, 2026, triggering this 54,925-unit award. These shares will actually vest only if Herzich remains in service on the related Evaluation Date, anticipated in the first quarter of 2027.
Solid Biosciences Inc. reported that CFO & Treasurer Kevin Tan acquired 56,647 restricted stock units tied to prior performance-based awards. Each unit represents a contingent right to receive one share of common stock, bringing his directly held RSU-based position reported in this filing to 56,647 units.
These RSUs relate to performance stock units granted on June 11, 2024, which vest in four equal 25% tranches upon achieving predetermined, non-market and non-financial performance milestones. The second milestone was certified as achieved on January 29, 2026, with the associated shares scheduled to vest only if he remains in service through an evaluation date anticipated in the first quarter of 2027.